Catalyst Wire Dossier Catalyst Wire Dossier

TAS-102 (trifluridine/tipiracil)

trifluridine/tipiracil · Taiho Oncology
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TAS-102 (trifluridine/tipiracil), covering 2025-03-19 to 2025-03-19. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study [Phase 1]

See pricing